{"entity":{"id":"nct05257590","kind":"trial","name":"CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma","aka":[],"tldr":"A phase 2 trial of Nivolumab in hepatocellular carcinoma and metastatic cancer, run by TaiRx, Inc., now recruiting.","summary":"CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT05257590 by TaiRx, Inc., with 95 participants planned, started 2022-05-23 and due to reach its primary completion in 2026-12-31. Interventions recorded: Nivolumab Injection [Opdivo], CVM-1118. Conditions listed: Hepatocellular Carcinoma, Advanced Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05257590","url":"https://clinicaltrials.gov/study/NCT05257590"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc","metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05257590","phase":"2","setting":"A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma","sponsor":"TaiRx, Inc.","enrolled":95,"outcomes":[]},"route":"/trials/nct05257590/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}]}}